US2015111825A1PendingUtilityA1
Osteocalcin as a treatment for male reproductive disorders
Est. expiryJan 19, 2030(~3.5 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 15/16A61P 15/00A61K 38/39A61P 15/10A61P 15/08
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods and compositions for treating, preventing, or diagnosing disorders related to reproduction in male mammals, preferably humans, are provided. The methods generally involve modulation of the OST-PTP signaling pathway or the PTP-1B signaling pathway involving gamma-carboxylase and osteocalcin. Disorders amenable to treatment by the methods include, but are not limited to, male infertility, low sperm count, impaired sperm motility, impaired sperm viability, low testosterone levels, reduced libido, erectile dysfunction, underdevelopment of testes, and excess apoptosis in testes.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treatment for increasing low sperm count, increasing low testosterone, or decreasing excessive apoptosis in testes in male mammals comprising administering to a male mammal in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of undercarboxylated/uncarboxylated osteocalcin and a pharmaceutically acceptable carrier or excipient.Join the waitlist — get patent alerts
Track US2015111825A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.